Comparative Pharmacology
Head-to-head clinical analysis: BUTABARB versus BUTALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARB versus BUTALAN.
BUTABARB vs BUTALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
None Documented
None Documented
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Category C
Category C
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."